Novavax ( (NVAX) ) has issued an announcement.
On March 7, 2025, Novavax received a notice terminating its advanced purchase agreement with the Canadian government due to the company’s failure to obtain regulatory approval for its COVID-19 vaccine by the end of 2024. As a result, Novavax will recognize $576 million as product revenue in the first quarter of 2025, but must refund $28 million in advanced payments to Canada. Additionally, a proposed memorandum of understanding related to in-country commitments is no longer feasible, allowing Novavax to release related funds.
More about Novavax
Novavax, Inc. operates in the biotechnology industry, primarily focusing on the development and commercialization of vaccines to prevent serious infectious diseases. Their main product is the COVID-19 vaccine, which has been a significant focus in recent years.
YTD Price Performance: -4.55%
Average Trading Volume: 4,329,496
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.32B
See more insights into NVAX stock on TipRanks’ Stock Analysis page.